Ignite Creation Date:
2025-12-24 @ 6:28 PM
Ignite Modification Date:
2025-12-29 @ 11:57 PM
Study NCT ID:
NCT04920968
Status:
RECRUITING
Last Update Posted:
2025-04-24
First Post:
2021-04-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Sponsor:
Maria Sklodowska-Curie National Research Institute of Oncology
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-05
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-25
First Submit QC Date:
None
Study First Post Date:
2021-06-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-21
Last Update Post Date:
2025-04-24
Last Update Post Date Type:
ACTUAL